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Accepted 12 July 2012AbstractObjective: The aim of this study was to evaluate the short-term therapeutic outcome of women with symptomatic uterine myomas treated with
laparoscopic uterine vessel occlusion (LUVO) or laparoscopic myomectomy (LM).
Methods: Ninety-five patients with symptomatic, uncomplicated myomas warranting surgical treatment who expressed a strong desire to retain
their uterus were included in this study. Fifty-two patients underwent LUVO and 43 underwent LM. The outcome was measured by comparing
blood loss, surgical time, postoperative recovery, postoperative pain (visual analog scale), complications, and success rate in both groups.
Results: The general characteristics of the patients were similar in both groups. There were no statistical differences in febrile morbidity,
complications, success rate, therapeutic efficacy (symptom relief), and satisfaction rate between the two groups. LUVO had advantages over LM,
including less surgical time, minimal blood loss, lower visual analog scale score, and rapid postoperative recovery.
Conclusions: Both LUVO and LM might be effective in the management of symptomatic myomas in selected cases, but LUVO seemed to be
more acceptable and less invasive in this 1-year short-term follow-up.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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http://dx.doi.org/10.1016/j.tjog.2012.09.008myomas are remarkably common [2]. Most of these myomas
are asymptomatic [3], although some may cause symptoms
that require a definite treatment [4]. There are many thera-
peutic strategies, but the management of women with symp-
tomatic uterine myomas depends on the patient’s age, the
reasons for treatment, the issue of fertility preservation, and
the patient’s preference [5]. Although hysterectomy has long
been considered a good choice if women have completed
childbearing [6], there are many other therapeutic approaches
available for preservation of the uterus [7e11], because
psychologically, the uterus has been regarded as the regulatorcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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organ, a source of energy and vitality, and a maintainer of
youth and attractiveness [12].
Laparoscopic surgery has seen significant improvement in
its techniques and instruments and has been developed and
used in the management of various kinds of benign diseases
[13e16]. Although some concerns about the role of laparo-
scopic myomectomy (LM) as a treatment option for symp-
tomatic uterine myomas are still present [17], it has become
more acceptable. Many comparison studies have evaluated the
safety and feasibility of abdominal myomectomy and LM
[18e22]. These studies showed that LM is clearly associated
with shorter hospitalization, faster recovery, less expense, less
pain, less blood loss, less fever, and fewer surgical compli-
cations compared with abdominal myomectomy. Pregnancy
rates and recurrence rates appear to be comparable between
LM and abdominal myomectomy [22]. A recent study
comparing LM and minilaparotomic (MLT) myomectomy also
showed the significant benefits of LM compared with MLT
myomectomy, if these treatments were applied in a highly
selected population (women with uterine fibroids with a size
less than 8 cm and the number less than 5) [21,22]. Therefore,
the use of LM can be considered as one of the choices in the
management of women with symptomatic uterine myomas.
Although the uterine-sparing treatment of choice for
symptomatic uterine myomas has been myomectomy
[23e26], uterine artery embolization (UAE) was introduced
in 1995 as an alternative technique for treating fibroid
tumors [27]. Since then it has become increasingly accepted
as a minimally invasive, uterine-sparing procedure, and
studies have reported relief of excessive menstrual bleeding
or pressure in 80e90% of patients [28e32]. These studies
have also shown a reduction in leiomyoma and uterus size
3e12 months after the procedure, as measured by ultraso-
nography or magnetic resonance imaging [30]. A similar
concept, known as laparoscopic uterine vessel occlusion
(LUVO) or laparoscopic uterine artery occlusion (LUAO),
was first reported as a treatment for myomas in 1999 or
earlier [33,34]. The difference between the LUAO and
LUVO methods is that LUAO is uterine artery occlusion
alone without simultaneous blockage of the uterine vessels
and the anastomotic sites between the uterine vessels and the
ovarian vessels, whereas LUVO is uterine artery occlusion
with simultaneous blockage of the uterine vessels and the
anastomotic sites between the uterine vessels and the ovarian
vessels. Similar relief of symptoms and reduction of the
uterus and leiomyoma size were reported in 2001 in a 7e12-
month follow-up of 87 patients after LUVO [35]. Since that
time, there has been rapid growth in the use of this treatment
with various modifications, such as simultaneous myomec-
tomy, and there has been considerable research into its
outcome [36e42]. For example, two studies with follow-ups
as long as 36 months after surgery have confirmed the results
of LUVO [43,44].
The aim of this study was to assess the short-term outcome
of LUVO and LM in the management of symptomatic uterine
myomas.Materials and methodsPatientsThe population of this study was derived from the Myoma
Registry in the Department of Obstetrics and Gynecology
(initiated from 1995). Women booked for myoma treatment
who had symptomatic uterine myomas were invited to partici-
pate in the current study. All the myoma treatment included
uterine-sparing and uterine-sacrificed treatments. Uterine-
sparing treatment included medical treatment, radiologic
approach, and surgical procedures; for example, myomectomy,
which was performed through traditional exploratory lapa-
rotomy, MLT, ultraminilaparotomy, laparoscopy, vagina, and
hysteroscopy approaches; and blockage of the uterine vessels,
such as LUVO, uterine vessel occlusion (UVO), LUAO, uterine
artery occlusion (UAO); or any combination of the above-
mentioned therapy. These women were informed that they
could choose to be treated with any one of the previously
mentioned procedures. All women were treated based on their
willingness and preference. Patients fulfilled the following
criteria of the Taiwan National Health Insurance Bureau
(NHIB) to comply with the definition of uncomplicated
myomas: symptomatic myoma; a wish to retain the uterus;
absence of previous abdominal or pelvic surgery; a number of
visible uterine masses (myomas) less than or equal to five
intramural or subserous myomas (without peduncle);
a maximum diameter of no more than 8 cm; and an absence of
prominent or significant pelvic adhesion on clinical evaluation.
The phrase “symptomatic” included either menstrual problems
such as menorrhagia and pain, or compression syndrome,
including a bulgelike sensation and frequency. To make this
study even more uniform and consistent, the general charac-
teristics of the patients in the two groups were evaluated
continuously during the study period using a limited number of
evaluated items, such as age, body mass index (BMI), and
biochemical blood data. This study was designed to compare
the short-term therapeutic outcome of women with uncompli-
cated uterine myomas treated with LUVO and LM. Therefore,
the following criteria should be met: a single operator;
uncomplicated myoma; complete 1-year follow-up; LUVO
alone or LM alone; and adequate sample size. There were 95
patients who were analyzed, including 52 women (54.7%)
undergoing LUVO (LUVO group) and the remaining 43
(45.3%) undergoing LM (LM group).Surgical proceduresBoth procedures were performed under general anesthesia
with the patient in the dorsolithotomy position and the bladder
catheterized.
The detailed procedure for the LUVO group has been
described previously [34e36]. In brief, after establishing
a laparoscopic surgical field, the anterior leaf of the broad
ligament was opened with scissors, keeping the peritoneum at
proper tension by shifting the uterus to the opposite side. A
vertical 2- to 3-cm incisionwasmade on the triangle enclosed by
Table 1
Baseline characteristics of the enrolled women.
LUVO (n ¼ 52) LM (n ¼ 43) p
Age (y) 41.8  3.5 42.3  3.3 0.408
Body mass index (kg/m2) 22.5  1.3 22.4  1.5 0.998
Preoperative HgB (g/dL) 9.4  1.8 9.7  1.7 0.391
Symptom
Pain 19.2% (n ¼ 10) 16.3% (n ¼ 7) 0.781
Menorrhagia 69.2% (n ¼ 36) 69.8% (n ¼ 30) 0.936
Bulge sensation 46.2% (n ¼ 24) 39.5% (n ¼ 17) 0.375
Frequency 40.4% (n ¼ 21) 34.9% (n ¼ 15) 0.415
Myoma
Number (n) 2.0  0.7 1.5  0.6 0.062
Max diameter (cm) 5.9  0.8 5.8  0.8 0.081
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ligament with careful dissection of the ureter and the internal
iliac artery, and adequate bleeding avoidance. The bilateral
uterine artery was then thoroughly occluded. The anatomic sites
between the uterine vessels and the ovarian vessels were also
occluded.
The detailed procedure used in the LM group has been
reported previously [26], with some modification. Myomas
were extracted through the 12-mm suprapubic port by mor-
cellation with the help of an electromechanical morcellator
(Ethicon, San Angelo, TX, USA). The myometrial edges were
closed in one or two layers, according to the depth of the
uterine wound by means of polyglactin 0 sutures.HgB ¼ hemoglobin level; LM ¼ laparoscopic myomectomy;
LUVO ¼ laparoscopic uterine vessel occlusion.Evaluation parametersThe parameters we considered for comparing the two
groups were: surgical time (minutes); blood loss; interval
between completing surgery and tolerance of food intake;
maximal fever; and complications such as blood transfusion,
wound infection, or hematoma. A visual analog scale (VAS)
applicable to the wound of each group was used to evaluate
postoperative pain for 24 hours after surgery. The VAS con-
sisted of a nongraduated 10-cm line ranging from “no pain” to
“pain as bad as it could be”.
Leiomyoma-related symptoms, for example menstrual
problems such as menorrhagia and pain, or compression
syndrome, including a bulgelike sensation and frequency, were
assessed using a yes/no improvement questionnaire at 3
months and 12 months after surgery. Recurrence was defined
as any presence of “no” in a yes/no improvement question-
naire at 3 months and 12 months after surgery. A yes/no
questionnaire was used at the discharge date and at the 3-
month and 12-month follow-ups to evaluate satisfaction.Statistical analysisA sample size of 44 in each group will have 80% power to
detect the differences in means of the selected outcome vari-
ables using a two-group Student t test with a 0.05 two-sided
significance level.
SPSS Software Version 15.0 for Windows (SPSS Inc., Chi-
cago, IL, USA) was used for statistical analysis. Descriptive
statistics were presented as means  standard deviation or
percentages. Means were compared by unpaired Student t test,
and proportions were compared by Chi-square or Fisher exact
tests, as appropriate. All calculated p values were two-tailed, and
a p value less than 0.05 was considered statistically significant.
Results
Mean age, BMI, symptoms resulting from myoma, preop-
erative hemoglobin level, number of myomas, and maximal
myoma diameter were similar in the two groups (Table 1).
Significantly, surgical time in the LUVO group was shorter
than in the LM group (36.9  4.9 minutes vs. 86.7  17.0
minutes); in addition, the amount of blood loss during theprocedure in the LUVO group was also less than that in the
LM group (24.7  5.8 mL vs. 143.7  81.7 mL). Post-
operative recovery was significantly better in the LUVO group
compared with the LM group because the mean of the
maximal postoperative temperature of the LUVO group was
significantly lower than that of the LM group, the VAS score
in the LUVO group was significantly lower than that in the
LM group, and food intake occurred sooner after surgery in
the LUVO group compared with the LM group.
The complication rate seemed to be higher in the LM
group, although it did not reach statistical significance
(Table 2). Five patients in the LM group were considered as
having complications and some of them had complications
comprising one or more events, two with abdominal
conversion due to technique difficulty, three with blood
transfusion because of a more than 500-mL blood loss during
surgery, two with ileus, and one with spiking fever
(39.0C). There was only one patient in the LUVO group
classified as having a complication. This patient had wide-
spread subcutaneous ecchymosis extending from the right
flank to the right thigh.
Most patients in both groups had symptom relief and
elevated hemoglobin levels (ranging from 85.7% to 94.4% in
the LUVO group and 83.3% to 95.3% in the LM group, based
on different kinds of symptoms) at the first follow-up, which
was evaluated at the end of 3 months after surgery (Table 3).
These symptom-improvement effects continued in the 1-year
follow-up in both groups. The cumulative recurrence rate in
the LUVO group was 9.6% and 15.4% at the end of 3 months
and 12 months after surgery, respectively, compared with
11.6% and 18.6% at the end of 3 months and 12 months after
surgery, respectively, in the LM group. Neither was statisti-
cally significant.
Most patients in both groups still had symptom relief and
had maintained the hemoglobin level (ranging from 80.0% to
90.4% in the LUVO group and 76.7% to 93.0% in the LM
group) at the end of 12 months after surgery (Table 3). Patients
in both groups showed a high immediate satisfaction rate
(100% in the LUVO group vs. 97.7% in the LM group), and this
satisfaction continued to the 3-month follow-up and the 1-year
follow-up, as seen in Table 3, without statistical difference.
Table 2
Surgical and postoperative parameters following LUVO and LM.
LUVO (n ¼ 52) LM (n ¼ 43) p
Surgical time (min) (95% CI) 36.9  4.9 (35.0e38.7) 86.7  17.0 (79.2e94.2) 0.0001
Blood loss (mL) (95% CI) 24.7  5.8 (22.9e26.5) 143.7  81.7 (102.8e184.7) 0.0001
Complications (95% CI) 1.9% (n ¼ 1) (0e5.6) 11.6% (n ¼ 5) (2.0e21.2) 0.069
Max fever (C) (95% CI) 37.4  0.2 (37.3e37.4) 37.7  0.5 (37.5e37.9) 0.0001
VAS (95% CI) 3.1  0.5 (2.9e3.2) 3.6  0.3 (3.5e3.7) 0.0001
Tolerance to food intake (h) (95% CI) 4.7  3.1 (3.7e5.6) 16.6  7.3 (13.9e19.2) 0.0001
Satisfaction rate (95% CI) 100% (52/52) 97.7% (42/43) (93.2e100) 0.323
CI ¼ confidence interval; complications ¼ detailed information in the text; LM ¼ laparoscopic myomectomy; LUVO ¼ laparoscopic uterine vessel occlusion;
VAS ¼ visual analog scale.
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In gynecologic and reproductive surgeries, patients have
been treated with different strategies and instruments
depending on what is currently in vogue [45e47]. There is
a growing consensus that patients undergoing surgery for
benign gynecologic diseases would benefit from a minimally
invasive approach [48]. The surgical accuracy and early
postoperative advantages of laparoscopy have been docu-
mented recently in the treatment of benign and malignant
gynecologic diseases [49,50]. In treating symptomatic uterine
myoma, both LUVO [6,9,10,30,31,33e42] and LM
[17e23,51] have been reported to provide satisfactory results.
We further confirmed in this study the concept that currently
available instruments make LM feasible, although the wide
application of this approach is limited by the size and number of
myomas reasonably removed and the technical difficulty of the
procedure and the laparoscopic suturing [17,32,50]. The criteria
for our study population were limited to the definition of
uncomplicated uterine myomas. However, the technical diffi-
culties might have been overestimated with careful selection of
a given population, such as those fulfilling the previously
mentioned criteria. In this study, almost all LM operations wereTable 3
Three-month and 12-month postoperative follow-up of the two groups of
women.
F-U
(months)
LUVO (n ¼ 52) LM (n ¼ 43) p
Hemoglobin level 3 12.0  0.5 11.8  0.7 0.191
12 11.7  0.7 11.5  0.9 0.951
Relief of symptoms (yes)
Pain 3 90.0% (9/10) 85.7% (6/7) 1.00
12 80.0% (8/10) 85.7% (6/7) 1.00
Menorrhagia 3 94.4% (34/36) 83.3% (28/30) 1.00
12 88.9% (32/36) 76.7% (23/30) 0.729
Bulge sensation 3 91.7% (22/24) 94.1% (16/17) 1.00
12 83.3% (20/24) 88.2% (15/17) 0.691
Frequency 3 85.7% (18/21) 93.3% (14/15) 0.627
12 85.7% (18/21) 80.0% (12/15) 1.00
Recurrence rate 3 9.6% (5/52) 11.6% (5/43) 0.750
12 15.4% (8/52) 18.6% (8/43) 0.676
Satisfaction rate 3 94.2% (45/52) 95.3% (41/43) 1.00
12 90.4% (47/52) 93.0% (40/43) 1.00
F-U ¼ follow-up; LM ¼ laparoscopic myomectomy; LUVO ¼ laparoscopic
uterine vessel occlusion.performed without difficulty. LM surgical time ranged from 56
minutes to 164 minutes, with a mean of 87 minutes. These data
were neither superior nor inferior to that of reports from all
available studies, because almost all spent more than 1 hour,
ranging from 62 minutes to 223 minutes, to complete the
surgery, except for one study reporting a range of 30e140
minutes [52]. Furthermore, compared with abdominal myo-
mectomy either through conventional exploratory laparotomy
(mean ¼ 99 minutes) or ultraminilaparotomy (mean ¼ 98
minutes) [10], LM was not inferior. With regard to the surgical
time, it was not surprising that LUVOwas significantly superior
to LM because the mean surgical time in the LUVO group was
only 37minutes, whichwas less than half of themean time spent
in the LM group (87 minutes).
The amount of estimated blood loss during LM in this study
was 144 mL; this seemed to be a little more than in our previous
study [23], which enrolled patients with the same criteria. The
blood loss in the LUVO group was minimal. Furthermore,
considering the complication rate in both groups, LUVO was
also superior to LM, although this difference did not reach
statistical significance. Based on the previously discussed
findings, LUVO was a more feasible procedure in the manage-
ment of uncomplicated uterine myoma, compared with LM.
In terms of the postoperative recovery in both groups,
LUVO also provided significant advantages, including less
postoperative pain (lower VAS score), fewer patients suffering
from postoperative fever with resultant lower mean tempera-
tures postoperatively, and a shorter interval from surgery to
tolerance to food intake.
LUVO had significant advantages, not only in shorter
surgical time and less blood loss, but also in better post-
operative recovery with lower VAS score, less fever, and
a shorter interval to food intake after surgery. In terms of 1-
year durable symptom control, they were evaluated at 3
months and 12 months after surgery, respectively.
All myoma-related symptoms in the LM group, either
menstrual problems such as menorrhagia and pain, or
compression syndrome, including a bulgelike sensation and
frequency, showed significant improvement, although they
varied from83.3% to 94.1%, at the end of 3months after surgery.
The hemoglobin level increased from 9.7 g/dL to 11.8 g/dL.
The efficacy of symptom relief was maintained for 1 year, with
76.7% to 88.2% of patients showing a symptom relief status. In
addition, the hemoglobin levelwas still maintained at 11.5 g/dL.
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LM group. A similar efficacy was shown in the LUVO group,
because symptom relief was reported as 85.7% to 94.4% at the
end of 3 months after surgery, and 80.0% to 88.9% at the end of
12 months after surgery. This also contributed to the more than
90% satisfaction rate up to the 1-year follow-up.
Although LUVO seems to have its advantages in this 1-year
study, there are many unanswered questions regarding LUVO
and LM. For example, the long-term outcome and future
reproductive outcome are unknown, and this study was not
a randomized study, which resulted in some selection bias. In
addition, we could not compare the myoma changes after each
treatment because, although the evaluable items in the LUVO
group were the complete disappearance of the myomas, the
decreased number of myomas (tumor shrinkage to invisible
status), and decreased size of the myomas, the myomas in the
LM group were theoretically removed during surgery; thus,
the reappearance of myomas in the LM group during follow-
up meant recurrence.
A publication evaluating the midterm clinical and first
reproductive results of the comparison between UAE and
myomectomy hinted that although UAE is less invasive and as
symptomatically effective and safe as myomectomy, myomec-
tomy appears to have superior reproductive outcomes in the first
2 years after treatment [53]. Therefore, some studies suggested
that myomectomy should be recommended as the treatment of
choice over UAE in most patients desiring future fertility [54],
even though most pregnancies following UAE have good
outcomes [55]. In comparing reproductive outcomes between
UAE and LUAO in women with symptomatic uterine myomas,
a recent study showed that the pregnancies of women who were
treated with uterine embolizationwere at significantly increased
risk for spontaneous abortion when compared with the preg-
nancies of women treated with LUAO [56]. In our previous
studies, we also demonstrated that immediate follicle-
stimulating hormone changes were not significant after LUAO
procedure, but women treated with LUVOwere associated with
a greater risk of a significant increase in follicle-stimulating
hormone level at the first month after operation, which may be
a reflection of diminished ovarian function, although the ther-
apeutic effects seemed to be better in those patients who
underwent LUVO [57,58].
In conclusion, this study showed the acceptability of both
LUVO and LM in the management of symptomatic women with
uncomplicated uterine myomas for the purpose of short-term
symptom control. The effectiveness of both procedures is
similar, but the LUVO group experienced less surgical and
postoperative suffering, so LUVO seemed to be a better choice in
this short-term 1-year follow-up. Based on these short-term
advantages of LUVO, the strategy to use this procedure in the
management of a certain group of patients might be worthy of
further study.
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